BioMarin Pharma rejected Andrea Sloan's "compassionate use" request to obtain a novel PARP-1/2 inhibitor cancer drug known as "BMN 673." Andrea is a 7-year, stage 3c ovarian cancer survivor. Andrea, along with her M.D. Anderson doctor and the FDA, believes that this new targeted therapy may help save or extend her life. Unfortunately, Andrea can not obtain BMN 673 without BioMarin's approval. If…
We are fundraising for the Ovarian Cancer Research Fund (OCRF). OCRF is the oldest and largest charity in the U.S. funding ovarian cancer research to better diagnose, treat, and ultimately cure ovarian cancer. Join us in supporting them.
My name is Paul Cacciatore and I am the founder of Libby's H*O*P*E*
The Ovarian Cancer Research Fund TV Commercial Featuring Andie MacDowell
Andrea Sloan, a 7-year, stage 3c survivor of ovarian cancer, is seeking a compassionate use exemption from pharmaceutical company BioMarin…Read More
Advocate for others needs help in a fight or her life
Today, May 8th, 2013, is the first World Ovarian Cancer Day…Read More
Karolinska Institute researchers report that "surgical treatment" for endometriosis may lower the risk of women developing ovarian cancer by up to 80% (http://www.webmd.boots.com/ovarian-cancer/news/20130411/endometriosis-surgery-ovarian-cancer). Surgical treatment involved removing one ovary (and…Read More